The DOI matches its Crossref record; 147 of the 147 references it cites were found in a registry or an index.
Regulation of antiviral T cell responses by type I interferons
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mechanisms of type-I- and type-II-interferon-mediated signalling
Platanias, L. C. (2005) · Nature Reviews Immunology · doi:10.1038/nri1604 · Cited by 3,491
Virus interference. I. the interferon
Isaacs, A., & Lindenmann, J. (1957) · Proceedings of the Royal Society of London. Series B - Biological Sciences · doi:10.1098/rspb.1957.0048 · Cited by 3,451
Follicular Helper CD4 T Cells (T FH )
Crotty, S. (2011) · Annual Review of Immunology · doi:10.1146/annurev-immunol-031210-101400 · Cited by 2,738
Interferon-inducible antiviral effectors
Sadler, A. J., & Williams, B. R. G. (2008) · Nature Reviews Immunology · doi:10.1038/nri2314 · Cited by 2,160
Interferons, interferon‐like cytokines, and their receptors
Pestka, S., Krause, C. D., & Walter, M. R. (2004) · Immunological Reviews · doi:10.1111/j.0105-2896.2004.00204.x · Cited by 1,766
Cross-presentation by dendritic cells
Joffre, O. P., Segura, E., Savina, A., & Amigorena, S. (2012) · Nature Reviews Immunology · doi:10.1038/nri3254 · Cited by 1,637
Wherry, E. J., Blattman, J. N., Murali-Krishna, K., van der Most, R., & Ahmed, R. (2003) · Journal of Virology · doi:10.1128/jvi.77.8.4911-4927.2003 · Cited by 1,610
Natural adjuvants: Endogenous activators of dendritic cells
Gallucci, S., Lolkema, M., & Matzinger, P. (1999) · Nature Medicine · doi:10.1038/15200 · Cited by 1,602
Induction of Dendritic Cell Differentiation by IFN-α in Systemic Lupus Erythematosus
Blanco, P., Palucka, A. K., Gill, M., Pascual, V., & Banchereau, J. (2001) · Science · doi:10.1126/science.1064890 · Cited by 1,266
Potent and Selective Stimulation of Memory-Phenotype CD8+ T Cells In Vivo by IL-15
Zhang, X., Sun, S., Hwang, I., Tough, D. F., & Sprent, J. (1998) · Immunity · doi:10.1016/s1074-7613(00)80564-6 · Cited by 1,245
Cited by
Approved Antiviral Drugs over the Past 50 Years
De Clercq, E., & Li, G. (2016) · Clinical Microbiology Reviews · doi:10.1128/cmr.00102-15 · Cited by 1,430
Shared and Distinct Functions of Type I and Type III Interferons
Lazear, H. M., Schoggins, J. W., & Diamond, M. S. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.025 · Cited by 1,138
Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery
Kowalski, P. S., Rudra, A., Miao, L., & Anderson, D. G. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.02.012 · Cited by 1,127
mRNA-based therapeutics: powerful and versatile tools to combat diseases
Qin, S., Tang, X., Chen, Y., Chen, K., Fan, N., Xiao, W., Zheng, Q., Li, G., Teng, Y., Wu, M., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01007-w · Cited by 771
The role of JAK-STAT signaling pathway and its regulators in the fate of T helper cells
Seif, F., Khoshmirsafa, M., Aazami, H., Mohsenzadegan, M., Sedighi, G., & Bahar, M. (2017) · Cell Communication and Signaling · doi:10.1186/s12964-017-0177-y · Cited by 768
Antibiotic‐Free Antibacterial Strategies Enabled by Nanomaterials: Progress and Perspectives
Wang, Y., Yang, Y., Shi, Y., Song, H., & Yu, C. (2020) · Advanced Materials · doi:10.1002/adma.201904106 · Cited by 700
Advances in mRNA Vaccines for Infectious Diseases
Zhang, C., Maruggi, G., Shan, H., & Li, J. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00594 · Cited by 665
Jamilloux, Y., Henry, T., Belot, A., Viel, S., Fauter, M., El Jammal, T., Walzer, T., François, B., & Sève, P. (2020) · Autoimmunity Reviews · doi:10.1016/j.autrev.2020.102567 · Cited by 658
Combination Cancer Therapy with Immune Checkpoint Blockade: Mechanisms and Strategies
Patel, S. A., & Minn, A. J. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.007 · Cited by 573
Newton, A. H., Cardani, A., & Braciale, T. J. (2016) · Seminars in Immunopathology · doi:10.1007/s00281-016-0558-0 · Cited by 476
Interplay between SARS-CoV-2 and the type I interferon response
Sa Ribero, M., Jouvenet, N., Dreux, M., & Nisole, S. (2020) · PLOS Pathogens · doi:10.1371/journal.ppat.1008737 · Cited by 443
“ISGs, along with other downstream molecules controlled by IFN-I (including proinflammatory cytokines), have diverse functions, ranging from direct inhibition of viral replication to the recruitment and activation of various immune cells [9, 10].”
BackgroundThree decades of messenger RNA vaccine development
Verbeke, R., Lentacker, I., De Smedt, S. C., & Dewitte, H. (2019) · Nano Today · doi:10.1016/j.nantod.2019.100766 · Cited by 342
The Roles of Type I Interferon in Bacterial Infection
Boxx, G. M., & Cheng, G. (2016) · Cell Host & Microbe · doi:10.1016/j.chom.2016.05.016 · Cited by 335
TLR Agonists as Vaccine Adjuvants Targeting Cancer and Infectious Diseases
Luchner, M., Reinke, S., & Milicic, A. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13020142 · Cited by 285
Type I interferons in tuberculosis: Foe and occasionally friend
Moreira-Teixeira, L., Mayer-Barber, K., Sher, A., & O’Garra, A. (2018) · Journal of Experimental Medicine · doi:10.1084/jem.20180325 · Cited by 282
Type I interferons instigate fetal demise after Zika virus infection
Yockey, L. J., Jurado, K. A., Arora, N., Millet, A., Rakib, T., Milano, K. M., Hastings, A. K., Fikrig, E., Kong, Y., Horvath, T. L., et al. (2018) · Science Immunology · doi:10.1126/sciimmunol.aao1680 · Cited by 255
Trial watch: Oncolytic viruses for cancer therapy
Vacchelli, E., Eggermont, A., Sautès-Fridman, C., Galon, J., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2013) · OncoImmunology · doi:10.4161/onci.24612 · Cited by 255
Trial watch: TLR3 agonists in cancer therapy
Le Naour, J., Galluzzi, L., Zitvogel, L., Kroemer, G., & Vacchelli, E. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1771143 · Cited by 239
Type I Interferon Responses Drive Intrahepatic T Cells to Promote Metabolic Syndrome
Ghazarian, M., Revelo, X. S., Nøhr, M. K., Luck, H., Zeng, K., Lei, H., Tsai, S., Schroer, S. A., Park, Y. J., Chng, M. H. Y., et al. (2017) · Science Immunology · doi:10.1126/sciimmunol.aai7616 · Cited by 190
Thieme, C. J., Anft, M., Paniskaki, K., Blazquez-Navarro, A., Doevelaar, A., Seibert, F. S., Hoelzer, B., Konik, M. J., Berger, M. M., Brenner, T., et al. (2020) · Cell Reports Medicine · doi:10.1016/j.xcrm.2020.100092 · Cited by 184
Minnaert, A.-K., Vanluchene, H., Verbeke, R., Lentacker, I., De Smedt, S. C., Raemdonck, K., Sanders, N. N., & Remaut, K. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113900 · Cited by 157
“It has however been suggested that the amount of type I IFN secretion as well as the timing of type I IFN signaling are crucial for the final outcome [16,34,208,212,220,223,224].”
T cell engagement of cross-presenting microglia protects the brain from a nasal virus infection
Moseman, E. A., Blanchard, A. C., Nayak, D., & McGavern, D. B. (2020) · Science Immunology · doi:10.1126/sciimmunol.abb1817 · Cited by 157
The bidirectional immune crosstalk in metabolic dysfunction-associated steatotic liver disease
Sawada, K., Chung, H., Softic, S., Moreno-Fernandez, M. E., & Divanovic, S. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.10.009 · Cited by 139
Interferons and the immunogenic effects of cancer therapy
Minn, A. J. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.09.007 · Cited by 130
Oncolytic virus-derived type I interferon restricts CAR T cell therapy
Evgin, L., Huff, A. L., Wongthida, P., Thompson, J., Kottke, T., Tonne, J., Schuelke, M., Ayasoufi, K., Driscoll, C. B., Shim, K. G., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17011-z · Cited by 128
De Beuckelaer, A., Pollard, C., Van Lint, S., Roose, K., Van Hoecke, L., Naessens, T., Udhayakumar, V. K., Smet, M., Sanders, N., Lienenklaus, S., et al. (2016) · Molecular Therapy · doi:10.1038/mt.2016.161 · Cited by 122
Shirley, J. L., Keeler, G. D., Sherman, A., Zolotukhin, I., Markusic, D. M., Hoffman, B. E., Morel, L. M., Wallet, M. A., Terhorst, C., & Herzog, R. W. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2019.11.011 · Cited by 79
Minter, M. R., Moore, Z., Zhang, M., Brody, K. M., Jones, N. C., Shultz, S. R., Taylor, J. M., & Crack, P. J. (2016) · Acta Neuropathologica Communications · doi:10.1186/s40478-016-0341-4 · Cited by 79
Van Hoecke, L., Roose, K., Ballegeer, M., Zhong, Z., Sanders, N. N., De Koker, S., Saelens, X., & Van Lint, S. (2020) · Molecular Therapy Nucleic Acids · doi:10.1016/j.omtn.2020.09.004 · Cited by 55
Jagger, B. W., Dowd, K. A., Chen, R. E., Desai, P., Foreman, B., Burgomaster, K. E., Himansu, S., Kong, W.-P., Graham, B. S., Pierson, T. C., et al. (2019) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiz338 · Cited by 53
Harrer, D. C., Schenkel, C., Bezler, V., Kaljanac, M., Hartley, J., Barden, M., Pan, H., Holzinger, A., Herr, W., & Abken, H. (2022) · Cells · doi:10.3390/cells11233839 · Cited by 24
Salman, E., Çelikbilek, N., Aydoğan, S., Özdem, B., Gökay, S., Kırca, F., Toyran, A., Bilici Salman, R., & Dinç, B. (2021) · Mikrobiyoloji Bulteni · doi:10.5578/mb.20219706 · Cited by 15
Type I IFN receptor blockade alleviates liver fibrosis through macrophage-derived STAT3 signaling
Park, S.-J., Garcia Diaz, J., Comlekoglu, T., & Hahn, Y. S. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1528382 · Cited by 10
“…in the expression of gene associated with viral protein interactions with cytokine receptors, drug metabolism, hepatic C, macrophages activation, innate immune regulation, cytokine-cytokine receptor interaction, PI3K-AKT pathway, and chemical carcinogenesis receptor activation (Figures 6, 7).”
Metadata
- Authors
- Crouse, J., Kalinke, U., & Oxenius, A.
- Venue
- Nature Reviews Immunology
- Published
- 2015-03-20
- Volume
- 15
- Issue
- 4
- Pages
- 231-242
- ISSN
- 1474-1733 (ISSN-L)
- 1474-1741
- OpenAlex
- W2016749309
- Cited by
- 479
- References
- 147
- FWCI
- 2.90
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.